Opiant Reports the Completion of Patient Enrolment in P-II Study for OPNT002 to Treat Alcohol Use Disorder
Shots:
- The P-II clinical trial evaluates the safety & tolerability of OPNT002 in patients (n=300) with Alcohol Use Disorder for a duration of 20wks. across Europe. The 1EPs of the study will be measured by the proportion of patients depicting an improvement in WHO Risk Levels of Alcohol Consumption
- Previously, the P-I study demonstrated that OPNT002 leads to maximum plasma concentrations that are ~50% higher vs orally administered naltrexone
- OPNT002 rapidly increases the plasma concentration of naltrexone after the dosing & therapy blockage of mu & delta-opiod receptors
Ref: Globe Newswire | Image: Opiant
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
